{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:01:34Z","timestamp":1790791294718,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:sup>90<\/jats:sup>Y\u2010ibritumomab\u2010tiuxetan (<jats:sup>90<\/jats:sup><jats:styled-content style=\"fixed-case\">YIT<\/jats:styled-content>) was used as a first\u2010line therapy for patients with early\u2010stage follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>) or marginal zone B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content>). Thirty\u2010one patients were treated, with an overall 3\u2010month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow\u2010up of 56\u00a0months, ten patients (32%) had disease relapse or progression. The progression\u2010free rates at 3 and 5\u00a0years were lower in males, patients with <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, stage <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> diseaseand non\u2010bulky disease, although they did not reach statistical significance. Grade 3\u20134 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. <jats:sup>90<\/jats:sup><jats:styled-content style=\"fixed-case\">YIT<\/jats:styled-content> was well tolerated, including in those patients over 60\u00a0years old, and achieved high response rates in patients with early\u2010stage low\u2010grade B\u2010cell lymphomas. Bulky disease did not adversely affect tumour response.<\/jats:p>","DOI":"10.1111\/bjh.13021","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T07:13:31Z","timestamp":1404803611000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["<sup>90<\/sup>Y\u2010ibritumomab tiuxetan radiotherapy as first\u2010line therapy for early stage low\u2010grade B\u2010cell lymphomas, including bulky disease"],"prefix":"10.1111","volume":"167","author":[{"given":"Felipe","family":"Samaniego","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Berkova","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijairam","family":"Selvaraj","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank K.","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25117"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2007.359"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010543"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_8_11_1","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non\u2010Hodgkin's lymphoma with (90)Y\u2010labeled anti\u2010CD20 monoclonal antibody","volume":"43","author":"Wagner H.N.","year":"2002","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2663"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.052"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13021","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:49:09Z","timestamp":1696265349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,8]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/bjh.13021"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13021","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,8]]},"assertion":[{"value":"2014-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}